Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-690514 + letrozole vs lapatinib + letrozole in recurrent or metastatic hormone receptor–positive breast cancer
2009-016622-13Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BMS-690514 in breast cancer (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Clinical benefit rate (CBR). Started Mar 2010; status: completed.
02
Drugs
BMS-690514
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-016622-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016622-13.